- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ipsos Healthcare Receives Award from Personal Connected Health Alliance
Ipsos Healthcare, the global healthcare division of Ipsos, has been given the New Member Award by the Personal Connected Health Alliance (PCHAlliance). PCHAlliance–a non-profit organization which mobilizes stakeholders to realise the full potential of personal connected health–presented Ipsos with the award at the Fall Member Summit yesterday, an event co-located with its 9th Annual Connected Health Conference in Boston, MA. The award was received by Ipsos Healthcare’s Head of Connected Health, Reena Sangar. Commenting on its decision to recognise Ipsos, PCHAlliance said, “In its first year as a member of PCHAlliance, Ipsos Healthcare has contributed significantly to the Alliance’s efforts through its Global Connected Health Survey, Digital Doctor Survey, and new efforts related to Digital Therapeutics. Ipsos is also exploring cutting-edge approaches to studying behaviours related to personal connected health that can inform a push towards sustained use of technology.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
